12 news items
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
MNKD
29 May 24
of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has agreed
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
MNKD
PULM
29 May 24
), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
MNKD
8 May 24
-101 which may allow us to bring this innovative product to patients more quickly." Revenue Highlights
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
MNKD
6 May 24
(NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
MNKD
1 May 24
(NASDAQ:MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical
mkj0ticzmi6jaohe35aogvw4qa
MNKD
30 Apr 24
of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will proceed
2oww0v2rhgp2fektgib22x3wl pull81kz6mk
MNKD
29 Apr 24
on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases
p5rjxs zui7if
MNKD
29 Apr 24
(NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices
zn1gxbozkxsf9eo
MNKD
26 Mar 24
of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We
ou5t463t1h8i003pqu1vm8qrfs
MNKD
11 Mar 24
and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan
074hq046u 7jomytxayc5y
MNKD
5 Mar 24
(NASDAQ:MNKD) focuses on the development and commercialization of innovative therapeutic products
gdyepmthnhsci6zpt9vmvynfx2c36 7v279
MNKD
4 Mar 24
on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine
- Prev
- 1
- Next